Crizotinib versus chemotherapy in advanced ALK-positive lung cancer
- PMID: 23724913
- DOI: 10.1056/NEJMoa1214886
Crizotinib versus chemotherapy in advanced ALK-positive lung cancer
Erratum in
-
Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer.N Engl J Med. 2015 Oct 15;373(16):1582. doi: 10.1056/NEJMx150036. N Engl J Med. 2015. PMID: 26466010 No abstract available.
Abstract
Background: In single-group studies, chromosomal rearrangements of the anaplastic lymphoma kinase gene (ALK) have been associated with marked clinical responses to crizotinib, an oral tyrosine kinase inhibitor targeting ALK. Whether crizotinib is superior to standard chemotherapy with respect to efficacy is unknown.
Methods: We conducted a phase 3, open-label trial comparing crizotinib with chemotherapy in 347 patients with locally advanced or metastatic ALK-positive lung cancer who had received one prior platinum-based regimen. Patients were randomly assigned to receive oral treatment with crizotinib (250 mg) twice daily or intravenous chemotherapy with either pemetrexed (500 mg per square meter of body-surface area) or docetaxel (75 mg per square meter) every 3 weeks. Patients in the chemotherapy group who had disease progression were permitted to cross over to crizotinib as part of a separate study. The primary end point was progression-free survival.
Results: The median progression-free survival was 7.7 months in the crizotinib group and 3.0 months in the chemotherapy group (hazard ratio for progression or death with crizotinib, 0.49; 95% confidence interval [CI], 0.37 to 0.64; P<0.001). The response rates were 65% (95% CI, 58 to 72) with crizotinib, as compared with 20% (95% CI, 14 to 26) with chemotherapy (P<0.001). An interim analysis of overall survival showed no significant improvement with crizotinib as compared with chemotherapy (hazard ratio for death in the crizotinib group, 1.02; 95% CI, 0.68 to 1.54; P=0.54). Common adverse events associated with crizotinib were visual disorder, gastrointestinal side effects, and elevated liver aminotransferase levels, whereas common adverse events with chemotherapy were fatigue, alopecia, and dyspnea. Patients reported greater reductions in symptoms of lung cancer and greater improvement in global quality of life with crizotinib than with chemotherapy.
Conclusions: Crizotinib is superior to standard chemotherapy in patients with previously treated, advanced non-small-cell lung cancer with ALK rearrangement. (Funded by Pfizer; ClinicalTrials.gov number, NCT00932893.).
Similar articles
-
First-line crizotinib versus chemotherapy in ALK-positive lung cancer.N Engl J Med. 2014 Dec 4;371(23):2167-77. doi: 10.1056/NEJMoa1408440. N Engl J Med. 2014. PMID: 25470694 Clinical Trial.
-
Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial.Lancet Oncol. 2017 Jul;18(7):874-886. doi: 10.1016/S1470-2045(17)30339-X. Epub 2017 Jun 9. Lancet Oncol. 2017. PMID: 28602779 Clinical Trial.
-
Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer.N Engl J Med. 2017 Aug 31;377(9):829-838. doi: 10.1056/NEJMoa1704795. Epub 2017 Jun 6. N Engl J Med. 2017. PMID: 28586279 Clinical Trial.
-
Crizotinib: a review of its use in the treatment of anaplastic lymphoma kinase-positive, advanced non-small cell lung cancer.Drugs. 2013 Dec;73(18):2031-51. doi: 10.1007/s40265-013-0142-z. Drugs. 2013. PMID: 24288180 Review.
-
Role of anaplastic lymphoma kinase inhibition in the treatment of non-small-cell lung cancer.Am J Health Syst Pharm. 2015 Sep 1;72(17):1456-62. doi: 10.2146/ajhp140836. Am J Health Syst Pharm. 2015. PMID: 26294238 Review.
Cited by
-
A multicenter, retrospective archive study of radiological and clinical features of ALK-positive non-small cell lung cancer patients and crizotinib efficacy.Medicine (Baltimore). 2024 May 24;103(21):e37972. doi: 10.1097/MD.0000000000037972. Medicine (Baltimore). 2024. PMID: 38787994 Free PMC article.
-
Rare Driver Mutations in Advanced, Oncogene-Addicted Non-Small Cell Lung Cancer: A North Italian, Real-World, Registry Experience.Diagnostics (Basel). 2024 May 15;14(10):1024. doi: 10.3390/diagnostics14101024. Diagnostics (Basel). 2024. PMID: 38786322 Free PMC article.
-
A novel subtype based on driver methylation-transcription in lung adenocarcinoma.J Cancer Res Clin Oncol. 2024 May 22;150(5):269. doi: 10.1007/s00432-024-05786-3. J Cancer Res Clin Oncol. 2024. PMID: 38777866 Free PMC article.
-
TIMM17A overexpression in lung adenocarcinoma and its association with prognosis.Sci Rep. 2024 Apr 17;14(1):8840. doi: 10.1038/s41598-024-59526-1. Sci Rep. 2024. PMID: 38632467 Free PMC article.
-
Development of crizotinib-associated renal cyst in a non-small cell lung cancer patient with ALK fusion: a case report and review of the literature.Diagn Pathol. 2024 Apr 14;19(1):58. doi: 10.1186/s13000-024-01480-7. Diagn Pathol. 2024. PMID: 38616252 Free PMC article. Review.
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical